IP Library Patent Application 11874674
Patent Application
App. No. 11/874,674

METHOD OF PREVENTING OR TREATING METABOLIC SYNDROME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/874,674
Abstract

Water-insoluble cellulose derivatives such as ethyl cellulose can be used to treat or prevent metabolic syndrome and/or one of the abnormalities of metabolic syndrome.

Claims (21)

1 . A method of preventing or treating metabolic syndrome or a symptom or condition associated with the metabolic syndrome in an individual comprising the step of administering to the individual an effective amount of a water-insoluble cellulose derivative.

2 . A method of preventing or treating one or more of the symptoms a) atherogenic dyslipidemia, b) insulin resistance, c) proinflammatory or inflammation state and d) prothrombotic state in an individual comprising the step of administering to the individual an effective amount of a water-insoluble cellulose derivative.

3 . A method of influencing the level of expression or the concentration of C-reactive protein, of Plasminogen Activator Inhibitor-1, or of hepatic lipase or of two or three thereof in a body tissue of an individual comprising the step of administering to the individual an effective amount of a water-insoluble cellulose derivative.

4 . A method of influencing the level of expression or the concentration of adiponectin in a body tissue of an individual comprising the step of administering to the individual an effective amount of a water-insoluble cellulose derivative.

5 . A method of preventing or treating a cardiovascular disease or Type II diabetes in an individual comprising the step of administering to the individual an effective amount of a water-insoluble cellulose derivative.

6 . The method of claim 1 wherein the water-insoluble cellulose derivative is ethyl cellulose.

7 . The method of claim 2 wherein the water-insoluble cellulose derivative is ethyl cellulose.

8 . The method of claim 3 wherein the water-insoluble cellulose derivative is ethyl cellulose.

9 . The method of claim 4 wherein the water-insoluble cellulose derivative is ethyl cellulose.

10 . The method of claim 5 wherein the water-insoluble cellulose derivative is ethyl cellulose.

11 . A medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement comprising an effective amount of a water-insoluble cellulose derivative for preventing or treating metabolic syndrome or a symptom or condition associated with the metabolic syndrome.

12 . A medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement comprising an effective amount of a water-insoluble cellulose derivative for preventing or treating one or more of the symptoms a) atherogenic dyslipidemia, b) insulin resistance, c) proinflammatory or inflammation state and d) prothrombotic state in an individual.

13 . A medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement comprising an effective amount of a water-insoluble cellulose derivative for influencing the level of expression or the concentration of C-reactive protein, of Plasminogen Activator Inhibitor-1 or of hepatic lipase or of two or three thereof in a body tissue of an individual.

14 . A medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement comprising an effective amount of a water-insoluble cellulose derivative for influencing the level of expression or the concentration of adiponectin in a body tissue of an individual.

15 . A medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement comprising an effective amount of a water-insoluble cellulose derivative for preventing or treating a cardiovascular disease or Type II diabetes in an individual.

16 . The medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement of claim 11 , wherein the water-insoluble cellulose derivative is ethyl cellulose.

17 . The medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement of claim 12 , wherein the water-insoluble cellulose derivative is ethyl cellulose.

18 . The medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement of claim 13 , wherein the water-insoluble cellulose derivative is ethyl cellulose.

19 . The medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement of claim 14 , wherein the water-insoluble cellulose derivative is ethyl cellulose.

20 . The medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement of claim 15 , wherein the water-insoluble cellulose derivative is ethyl cellulose.

21 . A medicament, pharmaceutical composition, food, food ingredient or supplement, or nutraceutical ingredient or supplement comprising ethyl cellulose as an active principle.

Assignments (2)
CHANGE OF NAME Recorded Mar 30, 2011
From: DOW GLOBAL TECHNOLOGIES INC.
To: DOW GLOBAL TECHNOLOGIES LLC
Reel/Frame 026065/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2010
From: YOKOYAMA, WALLACE
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
Reel/Frame 025507/0074 →